CliffBio
small molecule

CARBAMAZEPINE

CARBAMAZEPINE

Loss of exclusivity—loss of exclusivity
CompanyOsmotica Pharmaceutical →See this company's full patent-cliff portfolio

Drug detail

Brand nameCARBAMAZEPINE
Active ingredientCARBAMAZEPINE
Strength100MG
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2024
Marketing statusDISCN

More from Osmotica Pharmaceutical

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

CARBAMAZEPINE patent cliff — loss of exclusivity — | CliffBio